| abstract |
The present invention relates to a pharmaceutical composition comprising a synergic combination of a leukotriene-receptor antagonist, such as the active substance montelukast and its pharmaceutically acceptable salts, and an inverse antagonist of histamine H1, such as the active substance ketotifen and its pharmaceutically acceptable salts, which are formulated with pharmaceutically acceptable additives and/or excipients and/or vehicles in a single dosing unit to be administered orally, transdermally or by devices for oral or nasal inhalation. The composition is suitable for the treatment of atopic diseases such as asthma, allergic rhinitis and atopic dermatitis. |